Apo-Bromocriptine New Zealand - engelsk - Medsafe (Medicines Safety Authority)

apo-bromocriptine

apotex nz ltd - bromocriptine mesilate 2.9mg equivalent to bromocriptine 2.5 mg (2.9 - 3.0 mg) - tablet - 2.5 mg - active: bromocriptine mesilate 2.9mg equivalent to bromocriptine 2.5 mg (2.9 - 3.0 mg) excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose - prolactin dependent menstrual cycle disorders (amenorrhoea, oligomenorrhoea, galactorrhoea), and/or female infertility associated with hyperprolactinaemia or luteal phase deficiency: · bromocriptine may normalise the menstrual cycle and/or induce ovulation without ovarian overstimulation. treatment with bromocriptine is not curative and it is not effective in treating ovarian failure.

Remifentanil APOTEX remifentanil (as hydrochloride) 1 mg powder for injection vial Australien - engelsk - Department of Health (Therapeutic Goods Administration)

remifentanil apotex remifentanil (as hydrochloride) 1 mg powder for injection vial

apotex pty ltd - remifentanil hydrochloride, quantity: 1.097 mg - injection, powder for - excipient ingredients: hydrochloric acid; glycine - remifentanil is indicated:,- as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures, including cardiac surgery, in adults;,- as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical, but not cardiac procedures, in children aged 1?12 years;,- for continuation as an analgesic into the immediate post-operative period under the close supervision of medically-qualified persons trained in the use of anaesthetic agents, during transition to longer-acting analgesia following adult cardiac surgery ? when endotracheal intubation and controlled ventilation are anticipated;,- for provision of analgesia and sedation in mechanically-ventilated intensive care patients.

Remifentanil APOTEX remifentanil (as hydrochloride) 2 mg powder for injection vial Australien - engelsk - Department of Health (Therapeutic Goods Administration)

remifentanil apotex remifentanil (as hydrochloride) 2 mg powder for injection vial

apotex pty ltd - remifentanil hydrochloride, quantity: 2.194 mg - injection, powder for - excipient ingredients: glycine; hydrochloric acid - remifentanil is indicated:,- as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures, including cardiac surgery, in adults;,- as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical, but not cardiac procedures, in children aged 1?12 years;,- for continuation as an analgesic into the immediate post-operative period under the close supervision of medically-qualified persons trained in the use of anaesthetic agents, during transition to longer-acting analgesia following adult cardiac surgery ? when endotracheal intubation and controlled ventilation are anticipated;,- for provision of analgesia and sedation in mechanically-ventilated intensive care patients.

Remifentanil APOTEX remifentanil (as hydrochloride) 5 mg powder for injection vial Australien - engelsk - Department of Health (Therapeutic Goods Administration)

remifentanil apotex remifentanil (as hydrochloride) 5 mg powder for injection vial

apotex pty ltd - remifentanil hydrochloride, quantity: 5.485 mg - injection, powder for - excipient ingredients: hydrochloric acid; glycine - remifentanil is indicated:,- as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures, including cardiac surgery, in adults;,- as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical, but not cardiac procedures, in children aged 1?12 years;,- for continuation as an analgesic into the immediate post-operative period under the close supervision of medically-qualified persons trained in the use of anaesthetic agents, during transition to longer-acting analgesia following adult cardiac surgery ? when endotracheal intubation and controlled ventilation are anticipated;,- for provision of analgesia and sedation in mechanically-ventilated intensive care patients.